Article Figures & Data
Additional Files
Data Supplement
- Supplemental Data -
Supplementary Fig. S1. Schematic representation of the dosing regimen and staggered sampling design (PK) for all the treated groups during the first 4 weeks of the study.
Supplementary Fig. S2. (A) Determination of Serum creatinine (CRE) on day 0 and end point; Data were expressed as the mean ± S.D. (n = 6). *p < 0.05; **p <0.01. (B) Histological alterations of the kidney in CKD rats via comparison of representative imagines of the kidney histology by haematoxylin and eosin (H&E) staining.
Supplementary Fig. S3. General goodness-of-fit of the final model for rHuEPO (A) and romiplostim (B).
Supplementary Fig. S4. General goodness-of-fit of the final model for PD markers.
Supplementary Table S1. Pharmacokinetic parameters of rHuEPO (100 IU/kg or 1350 IU/kg) in Sprague-Dawley rats with CKD anemia in the absence or presence of romiplostim after intravenous administration TIW for 3 weeks. Data are expressed as the mean ± standard deviation (SD) (n = 3).
Supplementary Table S2. Pharmacokinetic parameters of romiplostim (30 μg/kg) in Sprague-Dawley rats with CKD anemia in the absence or presence of rHuEPO after subcutaneous injection of 0.03 mg/kg QW for 3 weeks.
Supplementary Table S3. Model estimates of the fixed- and random-effect PK parameters together with their relative standard errors.
- Supplemental Data -